Rallybio (RLYB) risk factors

78 risks, 28 new, 13 dropped, 14 reworded since the prior year. Rallybio added 28 risks driven almost entirely by its proposed merger with Candid. The company faces severe dilution and retained only 14 employees.

63 risks. Rallybio relies heavily on early-stage candidates RLYB212 for FNAIT and RLYB116, operating with a small team of 25 employees. The company faces significant dilution risks due to a lack of committed external funds and no commercial revenue history. Strict healthcare regulations, intellectual property hurdles, and heavy reliance on third-party manufacturers and clinical sites dominate the risk profile.